FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Lana McClements, Stephanie Annett, Anita Yakkundi, Martin O'Rourke, Andrea Valentine, Nermeen Moustafa, Abdelrahim Alqudah, Bruno M Simões, Fiona Furlong, Amy Short, Stuart A McIntosh, Helen O McCarthy, Robert B Clarke, Tracy Robson

ABSTRACT

BACKGROUND: Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more aggressive tumours with enhanced metastatic ability. Self-renewing cancer stem cells (CSCs) have been implicated in treatment resistance, recurrence and the development of metastatic disease. METHODS: In this study, we utilised in vitro, in vivo and ex vivo breast cancer models using ER+ MCF-7 and ER- MDA-MB-231 cells, as well as solid and metastatic breast cancer patient samples, to interrogate the effects of FKBPL and its peptide therapeutics on metastasis, endocrine therapy resistant CSCs and DLL4 and Notch4 expression. The effects of FKBPL overexpression or peptide treatment were assessed using a t-test or one-way ANOVA with Dunnett's multiple comparison test. RESULTS: We demonstrated that FKBPL overexpression or treatment with FKBPL-based therapeutics (AD-01, pre-clinical peptide /ALM201, clinical peptide) inhibit i) CSCs in both ER+ and ER- breast cancer, ii) cancer metastasis in a triple negative breast cancer metastasis model and iii) endocrine therapy resistant CSCs in ER+ breast cancer, via modulation of the DLL4 and Notch4 protein and/or mRNA expression. AD-01 was effective at reducing triple negative MDA-MB-231 breast cancer cell migration (n ≥ 3, p < 0.05) and invasion (n ≥ 3, p < 0.001) and this was translated in vivo where AD-01 inhibited breast cancer metastasis in MDA-MB-231-lucD3H1 in vivo model (p < 0.05). In ER+ MCF-7 cells and primary breast tumour samples, we demonstrated that ALM201 inhibits endocrine therapy resistant mammospheres, representative of CSC content (n ≥ 3, p < 0.05). Whilst an in vivo limiting dilution assay, using SCID mice, demonstrated that ALM201 alone or in combination with tamoxifen was very effective at delaying tumour recurrence by 12 (p < 0.05) or 21 days (p < 0.001), respectively, by reducing the number of CSCs. The potential mechanism of action, in addition to CD44, involves downregulation of DLL4 and Notch4. CONCLUSION: This study demonstrates, for the first time, the pre-clinical activity of novel systemic anti-cancer therapeutic peptides, ALM201 and AD-01, in the metastatic setting, and highlights their impact on endocrine therapy resistant CSCs; both areas of unmet clinical need. More... »

PAGES

351

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0

DOI

http://dx.doi.org/10.1186/s12885-019-5500-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113377817

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30975104


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Technology Sydney", 
          "id": "https://www.grid.ac/institutes/grid.117476.2", 
          "name": [
            "Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.", 
            "School of Pharmacy, Queen's University Belfast, Belfast, UK.", 
            "The School of Life Sciences, University of Technology Sydney, Sydney, Australia."
          ], 
          "type": "Organization"
        }, 
        "familyName": "McClements", 
        "givenName": "Lana", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal College of Surgeons in Ireland", 
          "id": "https://www.grid.ac/institutes/grid.4912.e", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK.", 
            "Department of Molecular and Cellular Therapeutics, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Annett", 
        "givenName": "Stephanie", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yakkundi", 
        "givenName": "Anita", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK.", 
            "Charles River Labs, 8-9 Spire Green Centre, Essex, Harlow, CM19 5TR, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "O'Rourke", 
        "givenName": "Martin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK.", 
            "Charles River Labs, 8-9 Spire Green Centre, Essex, Harlow, CM19 5TR, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Valentine", 
        "givenName": "Andrea", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moustafa", 
        "givenName": "Nermeen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hashemite University", 
          "id": "https://www.grid.ac/institutes/grid.33801.39", 
          "name": [
            "Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.", 
            "School of Pharmacy, Hashemite University, Amman, Jordan."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alqudah", 
        "givenName": "Abdelrahim", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Manchester", 
          "id": "https://www.grid.ac/institutes/grid.5379.8", 
          "name": [
            "Manchester Breast Centre, Division of Cancer Sciences, University of Manchester, Oglesby Cancer Research Building, Manchester, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sim\u00f5es", 
        "givenName": "Bruno M", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furlong", 
        "givenName": "Fiona", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Short", 
        "givenName": "Amy", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Belfast City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412914.b", 
          "name": [
            "Centre for Cancer Research and Cell Biology, Queen's University Belfast and Breast Surgery Department, Belfast City Hospital, Belfast, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "McIntosh", 
        "givenName": "Stuart A", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen's University Belfast", 
          "id": "https://www.grid.ac/institutes/grid.4777.3", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "McCarthy", 
        "givenName": "Helen O", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Manchester", 
          "id": "https://www.grid.ac/institutes/grid.5379.8", 
          "name": [
            "Manchester Breast Centre, Division of Cancer Sciences, University of Manchester, Oglesby Cancer Research Building, Manchester, UK."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clarke", 
        "givenName": "Robert B", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal College of Surgeons in Ireland", 
          "id": "https://www.grid.ac/institutes/grid.4912.e", 
          "name": [
            "School of Pharmacy, Queen's University Belfast, Belfast, UK. tracyrobson@rcsi.ie.", 
            "Department of Molecular and Cellular Therapeutics, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland. tracyrobson@rcsi.ie."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robson", 
        "givenName": "Tracy", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nature10983", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014607335", 
          "https://doi.org/10.1038/nature10983"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0055075", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022426445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18632/oncotarget.3410", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049700121"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more aggressive tumours with enhanced metastatic ability. Self-renewing cancer stem cells (CSCs) have been implicated in treatment resistance, recurrence and the development of metastatic disease.\nMETHODS: In this study, we utilised in vitro, in vivo and ex vivo breast cancer\u00a0models using ER+ MCF-7 and ER- MDA-MB-231 cells, as well as solid and metastatic breast cancer patient samples, to interrogate the effects of FKBPL and its peptide therapeutics on metastasis, endocrine therapy resistant CSCs and DLL4 and Notch4 expression. The effects of FKBPL overexpression or peptide treatment were assessed using a t-test or one-way ANOVA with Dunnett's multiple comparison test.\nRESULTS: We demonstrated that FKBPL overexpression or treatment with FKBPL-based therapeutics (AD-01, pre-clinical peptide /ALM201, clinical peptide) inhibit i) CSCs in both ER+ and ER- breast cancer, ii) cancer metastasis in a triple negative breast cancer metastasis model and iii) endocrine therapy resistant CSCs in ER+ breast cancer, via modulation of the DLL4 and Notch4 protein and/or mRNA expression. AD-01 was effective at reducing triple negative MDA-MB-231 breast cancer cell migration (n\u2009\u2265\u20093, p\u2009<\u20090.05) and invasion (n\u2009\u2265\u20093, p\u2009<\u20090.001) and this was translated in vivo where AD-01 inhibited breast cancer metastasis in MDA-MB-231-lucD3H1 in vivo model (p\u2009<\u20090.05). In ER+ MCF-7 cells and primary breast tumour samples, we demonstrated that ALM201 inhibits endocrine therapy resistant mammospheres, representative of CSC content (n\u2009\u2265\u20093, p\u2009<\u20090.05). Whilst an in vivo limiting dilution assay, using SCID mice, demonstrated that ALM201 alone or in combination with tamoxifen was very effective at delaying tumour recurrence by 12 (p\u2009<\u20090.05) or 21\u2009days (p\u2009<\u20090.001), respectively, by reducing the number of CSCs. The potential mechanism of action, in addition to CD44, involves downregulation of DLL4 and Notch4.\nCONCLUSION: This study demonstrates, for the first time, the pre-clinical activity of novel systemic anti-cancer therapeutic peptides, ALM201 and AD-01, in the metastatic setting, and highlights their impact on endocrine therapy resistant\u00a0CSCs; both areas of unmet clinical need.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-019-5500-0", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.", 
    "pagination": "351", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-019-5500-0"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113377817"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30975104"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-019-5500-0", 
      "https://app.dimensions.ai/details/publication/pub.1113377817"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106834_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5500-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5500-0'


 

This table displays all metadata directly associated to this object as RDF triples.

173 TRIPLES      21 PREDICATES      31 URIs      20 LITERALS      8 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-019-5500-0 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Ndc5ae041ec6b4c3c82415aab3e3a0f91
4 schema:citation sg:pub.10.1038/nature10983
5 https://doi.org/10.1371/journal.pone.0055075
6 https://doi.org/10.18632/oncotarget.3410
7 schema:datePublished 2019-12
8 schema:datePublishedReg 2019-12-01
9 schema:description BACKGROUND: Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more aggressive tumours with enhanced metastatic ability. Self-renewing cancer stem cells (CSCs) have been implicated in treatment resistance, recurrence and the development of metastatic disease. METHODS: In this study, we utilised in vitro, in vivo and ex vivo breast cancer models using ER+ MCF-7 and ER- MDA-MB-231 cells, as well as solid and metastatic breast cancer patient samples, to interrogate the effects of FKBPL and its peptide therapeutics on metastasis, endocrine therapy resistant CSCs and DLL4 and Notch4 expression. The effects of FKBPL overexpression or peptide treatment were assessed using a t-test or one-way ANOVA with Dunnett's multiple comparison test. RESULTS: We demonstrated that FKBPL overexpression or treatment with FKBPL-based therapeutics (AD-01, pre-clinical peptide /ALM201, clinical peptide) inhibit i) CSCs in both ER+ and ER- breast cancer, ii) cancer metastasis in a triple negative breast cancer metastasis model and iii) endocrine therapy resistant CSCs in ER+ breast cancer, via modulation of the DLL4 and Notch4 protein and/or mRNA expression. AD-01 was effective at reducing triple negative MDA-MB-231 breast cancer cell migration (n ≥ 3, p < 0.05) and invasion (n ≥ 3, p < 0.001) and this was translated in vivo where AD-01 inhibited breast cancer metastasis in MDA-MB-231-lucD3H1 in vivo model (p < 0.05). In ER+ MCF-7 cells and primary breast tumour samples, we demonstrated that ALM201 inhibits endocrine therapy resistant mammospheres, representative of CSC content (n ≥ 3, p < 0.05). Whilst an in vivo limiting dilution assay, using SCID mice, demonstrated that ALM201 alone or in combination with tamoxifen was very effective at delaying tumour recurrence by 12 (p < 0.05) or 21 days (p < 0.001), respectively, by reducing the number of CSCs. The potential mechanism of action, in addition to CD44, involves downregulation of DLL4 and Notch4. CONCLUSION: This study demonstrates, for the first time, the pre-clinical activity of novel systemic anti-cancer therapeutic peptides, ALM201 and AD-01, in the metastatic setting, and highlights their impact on endocrine therapy resistant CSCs; both areas of unmet clinical need.
10 schema:genre research_article
11 schema:inLanguage en
12 schema:isAccessibleForFree true
13 schema:isPartOf N3758b14f648b4a60a206169168a4af3e
14 Na2d30962c44541aca0afc793f2c8d6a2
15 sg:journal.1024632
16 schema:name FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
17 schema:pagination 351
18 schema:productId N35c035f2e03543b5b34e6a9fb8c8d6e7
19 N46c0ab1f53944ca6b8e1e679c9712a9b
20 Nc8eefd3c13f74d149e260f326fbc5ced
21 Nccae816551a242e6bebb579ac74e5ecb
22 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113377817
23 https://doi.org/10.1186/s12885-019-5500-0
24 schema:sdDatePublished 2019-04-16T06:25
25 schema:sdLicense https://scigraph.springernature.com/explorer/license/
26 schema:sdPublisher N00cfaa73a9fa47de9b6461d67595570a
27 schema:url https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5500-0
28 sgo:license sg:explorer/license/
29 sgo:sdDataset articles
30 rdf:type schema:ScholarlyArticle
31 N00cfaa73a9fa47de9b6461d67595570a schema:name Springer Nature - SN SciGraph project
32 rdf:type schema:Organization
33 N02ea9184171548fbb96cb4cb37401d52 schema:affiliation https://www.grid.ac/institutes/grid.4777.3
34 schema:familyName Furlong
35 schema:givenName Fiona
36 rdf:type schema:Person
37 N0337ea90ccc4438b9eed0b72a5ab1a37 rdf:first N586898a98fad4fda80e19b7da62791ae
38 rdf:rest N4241493a9dca4bc09f7916edea1830f8
39 N17b4120ee7ec46dc954d455393519fa4 rdf:first Ne5aa4aa1284349f89bc1d0ae53aa526a
40 rdf:rest Ncba3007b98814e51a5c8c1976fba4330
41 N35c035f2e03543b5b34e6a9fb8c8d6e7 schema:name nlm_unique_id
42 schema:value 100967800
43 rdf:type schema:PropertyValue
44 N3758b14f648b4a60a206169168a4af3e schema:volumeNumber 19
45 rdf:type schema:PublicationVolume
46 N37af5e65afa846038b0485ce66f79c65 schema:affiliation https://www.grid.ac/institutes/grid.5379.8
47 schema:familyName Simões
48 schema:givenName Bruno M
49 rdf:type schema:Person
50 N411887ee06734a89892cb5be6ddd0dd8 schema:affiliation https://www.grid.ac/institutes/grid.4912.e
51 schema:familyName Robson
52 schema:givenName Tracy
53 rdf:type schema:Person
54 N4241493a9dca4bc09f7916edea1830f8 rdf:first N7d5ffdebf2654b97b958254aa29704c4
55 rdf:rest N17b4120ee7ec46dc954d455393519fa4
56 N46c0ab1f53944ca6b8e1e679c9712a9b schema:name pubmed_id
57 schema:value 30975104
58 rdf:type schema:PropertyValue
59 N4c834b3a8041423999592954fd1f01c3 rdf:first Nd614cfb902944fa7b8970d29f9becce6
60 rdf:rest Ne77213e098234bfb95b31ad62c012d2d
61 N4e2254a3e48d4cef8f9a062b6baefe36 schema:affiliation https://www.grid.ac/institutes/grid.4777.3
62 schema:familyName Short
63 schema:givenName Amy
64 rdf:type schema:Person
65 N5221f5b31a8740a98928a8df6b6efb45 rdf:first Nde55ba40b726475baaf93d236260ffeb
66 rdf:rest Nc602bf3a7ca443a89501c6d5f6890275
67 N534ba9f1d4314e389bba20e3dfa3be6e rdf:first N02ea9184171548fbb96cb4cb37401d52
68 rdf:rest N8037083d23554930923722f974cb482a
69 N57796064dfae4cb7a8bb01e386b5bcd4 schema:affiliation https://www.grid.ac/institutes/grid.4777.3
70 schema:familyName O'Rourke
71 schema:givenName Martin
72 rdf:type schema:Person
73 N586898a98fad4fda80e19b7da62791ae schema:affiliation https://www.grid.ac/institutes/grid.4777.3
74 schema:familyName Valentine
75 schema:givenName Andrea
76 rdf:type schema:Person
77 N5ff51d79904041cb8f966c03a34ec11b schema:affiliation https://www.grid.ac/institutes/grid.5379.8
78 schema:familyName Clarke
79 schema:givenName Robert B
80 rdf:type schema:Person
81 N70fd01d8ed1947668729cb31a2f51db6 schema:affiliation https://www.grid.ac/institutes/grid.117476.2
82 schema:familyName McClements
83 schema:givenName Lana
84 rdf:type schema:Person
85 N7d5ffdebf2654b97b958254aa29704c4 schema:affiliation https://www.grid.ac/institutes/grid.4777.3
86 schema:familyName Moustafa
87 schema:givenName Nermeen
88 rdf:type schema:Person
89 N8037083d23554930923722f974cb482a rdf:first N4e2254a3e48d4cef8f9a062b6baefe36
90 rdf:rest N4c834b3a8041423999592954fd1f01c3
91 Na2d30962c44541aca0afc793f2c8d6a2 schema:issueNumber 1
92 rdf:type schema:PublicationIssue
93 Nb3c7c7fc6edd4eb09b67af89df7fb191 schema:affiliation https://www.grid.ac/institutes/grid.4912.e
94 schema:familyName Annett
95 schema:givenName Stephanie
96 rdf:type schema:Person
97 Nbf463028bccd45bdb2960ba47af3260b schema:affiliation https://www.grid.ac/institutes/grid.4777.3
98 schema:familyName McCarthy
99 schema:givenName Helen O
100 rdf:type schema:Person
101 Nc602bf3a7ca443a89501c6d5f6890275 rdf:first N57796064dfae4cb7a8bb01e386b5bcd4
102 rdf:rest N0337ea90ccc4438b9eed0b72a5ab1a37
103 Nc8485c4919e64359aa3cbb602d386e1c rdf:first Nb3c7c7fc6edd4eb09b67af89df7fb191
104 rdf:rest N5221f5b31a8740a98928a8df6b6efb45
105 Nc8eefd3c13f74d149e260f326fbc5ced schema:name dimensions_id
106 schema:value pub.1113377817
107 rdf:type schema:PropertyValue
108 Ncba3007b98814e51a5c8c1976fba4330 rdf:first N37af5e65afa846038b0485ce66f79c65
109 rdf:rest N534ba9f1d4314e389bba20e3dfa3be6e
110 Nccae816551a242e6bebb579ac74e5ecb schema:name doi
111 schema:value 10.1186/s12885-019-5500-0
112 rdf:type schema:PropertyValue
113 Nd07074d3ca4b41f4833df05d89015f29 rdf:first N5ff51d79904041cb8f966c03a34ec11b
114 rdf:rest Nf95ebf543fc7496db75c2d3038971f1c
115 Nd614cfb902944fa7b8970d29f9becce6 schema:affiliation https://www.grid.ac/institutes/grid.412914.b
116 schema:familyName McIntosh
117 schema:givenName Stuart A
118 rdf:type schema:Person
119 Ndc5ae041ec6b4c3c82415aab3e3a0f91 rdf:first N70fd01d8ed1947668729cb31a2f51db6
120 rdf:rest Nc8485c4919e64359aa3cbb602d386e1c
121 Nde55ba40b726475baaf93d236260ffeb schema:affiliation https://www.grid.ac/institutes/grid.4777.3
122 schema:familyName Yakkundi
123 schema:givenName Anita
124 rdf:type schema:Person
125 Ne5aa4aa1284349f89bc1d0ae53aa526a schema:affiliation https://www.grid.ac/institutes/grid.33801.39
126 schema:familyName Alqudah
127 schema:givenName Abdelrahim
128 rdf:type schema:Person
129 Ne77213e098234bfb95b31ad62c012d2d rdf:first Nbf463028bccd45bdb2960ba47af3260b
130 rdf:rest Nd07074d3ca4b41f4833df05d89015f29
131 Nf95ebf543fc7496db75c2d3038971f1c rdf:first N411887ee06734a89892cb5be6ddd0dd8
132 rdf:rest rdf:nil
133 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
134 schema:name Medical and Health Sciences
135 rdf:type schema:DefinedTerm
136 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
137 schema:name Oncology and Carcinogenesis
138 rdf:type schema:DefinedTerm
139 sg:journal.1024632 schema:issn 1471-2407
140 schema:name BMC Cancer
141 rdf:type schema:Periodical
142 sg:pub.10.1038/nature10983 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014607335
143 https://doi.org/10.1038/nature10983
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1371/journal.pone.0055075 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022426445
146 rdf:type schema:CreativeWork
147 https://doi.org/10.18632/oncotarget.3410 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049700121
148 rdf:type schema:CreativeWork
149 https://www.grid.ac/institutes/grid.117476.2 schema:alternateName University of Technology Sydney
150 schema:name Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
151 School of Pharmacy, Queen's University Belfast, Belfast, UK.
152 The School of Life Sciences, University of Technology Sydney, Sydney, Australia.
153 rdf:type schema:Organization
154 https://www.grid.ac/institutes/grid.33801.39 schema:alternateName Hashemite University
155 schema:name Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
156 School of Pharmacy, Hashemite University, Amman, Jordan.
157 rdf:type schema:Organization
158 https://www.grid.ac/institutes/grid.412914.b schema:alternateName Belfast City Hospital
159 schema:name Centre for Cancer Research and Cell Biology, Queen's University Belfast and Breast Surgery Department, Belfast City Hospital, Belfast, UK.
160 rdf:type schema:Organization
161 https://www.grid.ac/institutes/grid.4777.3 schema:alternateName Queen's University Belfast
162 schema:name Charles River Labs, 8-9 Spire Green Centre, Essex, Harlow, CM19 5TR, UK.
163 School of Pharmacy, Queen's University Belfast, Belfast, UK.
164 rdf:type schema:Organization
165 https://www.grid.ac/institutes/grid.4912.e schema:alternateName Royal College of Surgeons in Ireland
166 schema:name Department of Molecular and Cellular Therapeutics, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland.
167 Department of Molecular and Cellular Therapeutics, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, RCSI, Dublin, Ireland. tracyrobson@rcsi.ie.
168 School of Pharmacy, Queen's University Belfast, Belfast, UK.
169 School of Pharmacy, Queen's University Belfast, Belfast, UK. tracyrobson@rcsi.ie.
170 rdf:type schema:Organization
171 https://www.grid.ac/institutes/grid.5379.8 schema:alternateName University of Manchester
172 schema:name Manchester Breast Centre, Division of Cancer Sciences, University of Manchester, Oglesby Cancer Research Building, Manchester, UK.
173 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...